|
|
|
|
|
|
by keepper
2993 days ago
|
|
|
Odd they don't mention the cuban work on this field. "Researchers with Cuba’s Center for Molecular Immunology have developed and approved an immunologic cancer therapy that improves survivability for certain types of cancers in some cases; as of January 2017, the drug has begun clinical trials for the treatment in the United States." https://www.usatoday.com/story/news/world/2018/01/09/cuba-ha... |
|
|
https://www.ncbi.nlm.nih.gov/pubmed/25420897
https://www.frontiersin.org/articles/10.3389/fonc.2012.00150...
This drug has completed a limited Phase II study in 2014 (71 patients), adding about 5 months of life over the control group (11 mo vs 6 mo). Then it began a large international phase III NSCLC (lung) study which apparently hasn't ended yet.
It's approved for use in Cuba and Argentina, probably only for lung cancer.